GC
IMDZ

Guggenheim Capital’s Immune Design Corp. IMDZ Stock Holding History

Guggenheim Capital’s Portfolio IMDZ Stock Details IMDZ Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q2 		– Sell
-11,306
Closed -$37K – 2813
2018
Q1 		$37K Buy
+11,306
New +$40K ﹤0.01% 2718

Other funds holding IMDZ

EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
VVM
Versant Venture Management San Francisco, California $141M AUM 190.82% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PAI
ProQuest Associates IV Naples, Florida $53M AUM 3.35% 1-Year Est. Return
BCPEM
Bain Capital Public Equity Management Boston, Massachusetts $1.05B AUM 25.71% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Guggenheim Capital's IMDZ Position: Q2 2018 in Review

Guggenheim Capital sold out of Immune Design Corp. (IMDZ) in Q2 2018, closing a stake of 11,306 shares — an estimated $37K sold.

Guggenheim Capital first reported a position in IMDZ in Q1 2018 and held it in 1 quarter. The position peaked at $37K in Q1 2018. 80 funds tracked by Wall St. Rank hold IMDZ as of Q2 2018.

  • Guggenheim Capital reported no remaining Immune Design Corp. position as of Q2 2018 after selling out during the quarter.
  • Guggenheim Capital sold 11,306 Immune Design Corp. shares in Q2 2018, an estimated $37K.
  • Guggenheim Capital first reported a position in Immune Design Corp. in Q1 2018 and held it in 1 quarter.
  • Guggenheim Capital's Immune Design Corp. position peaked at $37K in Q1 2018.
  • 80 funds tracked by Wall St. Rank held Immune Design Corp. as of Q2 2018.

Based on Guggenheim Capital's 13F filing for Q2 2018, filed 14 Aug 2018.